Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 07:30 ET | Source: Marvel Biosciences Corp.

Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit

Marvel Biosciences to participate in 2nd Neuroscience Innovation Partnering & Licensing Summit, allowing Marvel to showcase its progress on global stage
April 23, 2026 07:02 ET | Source: Ocugen

Ocugen to Present at April 2026 Investor and Industry Conferences

MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
April 23, 2026 07:00 ET | Source: AAVantgarde

AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study

MILAN, April 23, 2026 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering next-generation gene therapies for inherited retinal diseases (IRDs) has...
April 23, 2026 07:00 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived...
April 23, 2026 07:00 ET | Source: Transcenta

Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer

PRINCETON, N.J. and SUZHOU, China, April 23, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in...
April 23, 2026 07:00 ET | Source: Jade Biosciences

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on...
April 23, 2026 07:00 ET | Source: Antag Therapeutics

Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions

Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces that it will...
April 23, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
April 23, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
April 23, 2026 04:00 ET | Source: Epitopea

Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer

CAMBRIDGE, United Kingdom and MONTREAL, April 23, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic biotech developing off-the-shelf, durable, RNA-based cancer immunotherapies, today announced that...